Main Sector
Biotech Subsector
Medtech Subsector
Diagnostics Subsector
Indications
Biotech Phase of Development
Medtech/Diagnostic Phase of Development
Index
Countries
Reset

Arthur Roach United Kingdom

Parkinson's UK supports projects that aim to bring new treatments or a cure to Parkinson's, at the drug discovery and early clinical develoment stages.  Typically support is at the level of $0.5M - $2M per year.  We prefer to invest in projects in a virtual company model but may also invest at the pre-company stage or in projects in existing larger companies.  Treatments directed at broadly applicable neurodegeneration mechanisms such as neuroinflammation and oxidative damage are within our scope, as are symtomatic treatments.  Funding recipients may be located in the UK, Europe or overseas.

Website:
www.parkinsonsvirtualbiotech.com
Main Sector
Biotech Subsector
Indications
Biotech Phase of Development
Year Founded
1970
Parkinson's UK
Director of Research 
Bio

Arthur Roach is representing both Parkinson's UK and Chord Therapeutics at this meeting.

Arthur Roach is Director of Research at Parkinson’s UK, where he is responsible for the strategy to convert the demands and priorities of people living with Parkinson’s into better treatments and a deeper understanding of the condition.  In the current five-year strategic period Parkinson’s UK is investing £40 million in university research grants, international collaborations and data sharing, drug discovery and early clinical development of new treatments, and promoting the greater involvement and participation of people with Parkinson’s in research.  He brings to this role over 25 years of experience of research into Parkinson’s, Alzheimer’s, multiple sclerosis and other neurodegenerative diseases and the discovery and development of new treatments (DuPont, Bristol-Myers Squibb, Merck Serono).

Arthur is also the founder of Chord Therapeutics, a single-asset virtual biotech dedicted to clinical development of CRD1 as a new treatment for neuromyelitis optica and other rare autoimmune neurological conditions.  Chord  is seeking financing for a three-year programme to establish clinical proof of concept in two indications.